New gel shows promise for shrinking painful skin tumors in rare genetic condition
NCT ID NCT05005845
First seen Feb 17, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study tested a gel called NFX-179 on skin tumors (cutaneous neurofibromas) in 199 adults with neurofibromatosis type 1. Participants applied the gel daily for 6 months to up to 10 tumors. The goal was to see if the gel safely shrinks the tumors. Results showed some tumors reduced in size, but ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Apex Clinical Research Center, LLC
Mayfield Heights, Ohio, 44124, United States
-
Center for Dermatology Clinical Research, Inc.
Fremont, California, 94538, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Dawes Fretzin Clinical Research Group
Indianapolis, Indiana, 46250, United States
-
Derm Dox Center for Dermatology
Sugarloaf, Pennsylvania, 18249, United States
-
Dermatology Treatment and Research Center
Dallas, Texas, 75230, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Minnesota Clinical Study Center
New Brighton, Minnesota, 55112, United States
-
Northshore University HealthSystem
Evanston, Illinois, 60077, United States
-
Northwest Arkansas Clinical Trials Center, PLLC
Rogers, Arkansas, 72758, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Sadick Research Group, LLC
New York, New York, 10075, United States
-
Skin Search of Rochester, Inc.
Rochester, New York, 14623, United States
-
Skin Specialists, P.C.
Omaha, Nebraska, 68144, United States
-
The Education & Research Foundation, Inc.
Lynchburg, Virginia, 24501, United States
-
The Johns Hopkins School of Medicine
Baltimore, Maryland, 21287, United States
-
UTHealth McGovern Medical School
Houston, Texas, 77030, United States
-
University Clinical Trials, Inc.
San Diego, California, 92123, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205-7199, United States
-
University of Florida
Gainesville, Florida, 32610, United States
-
University of Utah
Salt Lake City, Utah, 84108, United States
-
Wake Forest School of Medicine
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.